Discovery and Preclinical Testing:

Target Identification: Researchers identified dipeptidyl peptidase-4 (DPP-4) as a potential target for type 2 diabetes treatment.Animal studies demonstrated its ability to improve glycemic control without significant adverse effects.DPP-4 is an enzyme that deactivates incretin hormones, which are involved in the regulation of blood glucose levels.